person

Marion Leboyer, MD PhD

ORCID 0000-0001-5473-3697

as of 2026-07-01

Monitor this Ask about this

at a glance

Roles: Study Chair, Author, Investigator+Author

KOL signal score 12

4 publications · 1 high-value

Cross-drug reach: 1 competitor drugs

Synthesized from structured facts only — each point cited above.

Profile

Affiliation

Fondation FondaMental

Roles

Study Chair, Author, Investigator+Author

KOL signal

Publications

4 (1 high-value)

Trial investigator

yes

Publishes on

1 drugs

Amisulpride

Trials led

Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression

NCT05480826—Recruiting

Publications & congress

QT Interval, Antipsychotics and Correlates Among Patients with Schizophrenia: Cross-Sectional Data from the Multicentric Real-World FACE-SZ.

Drug safety · 2025 · high-value

Immunogenetic Variants in Major Mental and Neurodevelopmental Disorders.

Biological psychiatry · 2026

Using blood methylomes to predict response to amisulpride in the first-episode psychosis in the OPTiMiSE cohort.

Translational psychiatry · 2025

Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial.

Schizophrenia bulletin · 2023

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

publishes on

Amisulpride

drug

STUDY_CHAIR

Familial and Functional Study of Genetic Variants Identified in People With Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder or Resistant Depression

trial